Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) has been assigned a consensus recommendation of “Buy” from the six ratings firms that are currently covering the company, MarketBeat reports. Six analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $14.06.

Several equities analysts recently weighed in on the stock. Seaport Global Securities assumed coverage on shares of Rexahn Pharmaceuticals in a report on Friday. They set a “buy” rating on the stock. Ifs Securities restated an “outperform” rating on shares of Rexahn Pharmaceuticals in a report on Monday, August 7th. Zacks Investment Research upgraded shares of Rexahn Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a report on Wednesday. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Rexahn Pharmaceuticals in a report on Monday, August 14th. Finally, Rodman & Renshaw restated a “buy” rating and set a $19.50 target price on shares of Rexahn Pharmaceuticals in a report on Friday, June 9th.

Shares of Rexahn Pharmaceuticals (NYSEMKT RNN) opened at 2.4441 on Friday. The firm’s market capitalization is $69.56 million. The stock has a 50 day moving average price of $2.32 and a 200 day moving average price of $2.21. Rexahn Pharmaceuticals has a 52 week low of $0.39 and a 52 week high of $7.10.

Hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC lifted its holdings in Rexahn Pharmaceuticals by 17.6% in the 1st quarter. Renaissance Technologies LLC now owns 5,758,391 shares of the company’s stock worth $2,937,000 after buying an additional 862,000 shares in the last quarter. Sabby Management LLC acquired a new position in Rexahn Pharmaceuticals in the 2nd quarter worth $706,000. Finally, Susquehanna International Group LLP acquired a new position in Rexahn Pharmaceuticals in the 2nd quarter worth $2,905,000.

WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/06/rexahn-pharmaceuticals-inc-rnn-receives-consensus-rating-of-buy-from-brokerages.html.

About Rexahn Pharmaceuticals

Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.

Analyst Recommendations for Rexahn Pharmaceuticals (NYSEMKT:RNN)

Receive News & Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.